Suchen
Prelude Therapeutics Inc
PRLDZur Watchlist hinzufügen
3.990USD
-0.320-7.42%
Handelsschluss 09-24 16:00（ET）
317.80MMarktkapitalisierung
VerlustKGV TTM
Über Prelude Therapeutics Inc Unternehmen
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Prelude Therapeutics Inc Profil
BörsenkürzelPRLD
Name des UnternehmensPrelude Therapeutics Inc
IPO-datumSep 25, 2020
CEOVaddi (Krishna)
Anzahl der mitarbeiter131
WertpapierartOrdinary Share
GeschäftsjahresendeSep 25
Addresse175 Innovation Boulevard
StadtWILMINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19805
Telefon13024671280
Websitehttps://preludetx.com/
BörsenkürzelPRLD
IPO-datumSep 25, 2020
CEOVaddi (Krishna)
Führungskräfte von Prelude Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Mr. Sean P. Brusky
Mr. Sean P. Brusky
Chief Business Officer
Chief Business Officer
100.00K
--
Mr. Sean P. Brusky
Mr. Sean P. Brusky
Chief Business Officer
Chief Business Officer
100.00K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Prelude Therapeutics Inc?
Die fünf größten Anteilseigner von Prelude Therapeutics Inc sind: Dr. Krishna (Kris) Vaddi, Ph.D.
Wie viele Institutionen halten Anteile an Prelude Therapeutics Inc (PRLD)?
Mit Stand vom 2026Q1 halten 149 Institutionen Anteile an Prelude Therapeutics Inc, mit einem Gesamtmarktwert von etwa 30.05M, was 57.50% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -7756404.00 gestiegen.